No Drug Price Hikes In Pakistan
Pakistan's government has announced that there has been no increase in the prices of medicines on the domestic market following the recent devaluation of the Pakistani rupee, according to the Pakistan Times.
The statement was made by a government minister replying to a member of the opposition, who claimed that the prices of drugs had gone up for the third time in 1995, with prices having risen by up to 35% during the year. In addition, the Drugs Association of Karachi has said that there has been an upward trend in pharmaceutical prices.
The minister added that the pressure was there from pharmaceutical producers to raise prices, but that the government is aiming not to let this happen. He added that the last price increase was in July 1995 and the government is monitoring prices closely.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze